Developer docs
API playgroundTry for free, no card

Search company profiles

Crescendo Biologics

Full company profile

uuid00023f7

Namestring
Crescendo Biologics
Legal namestring
Crescendo Biologics Limited
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Crescendo Biologics is a privately held, clinical-stage immuno-oncology company headquartered at the Babraham Research Campus in Cambridge, UK. Founded in 2009, the company develops novel T cell enhancing therapeutics built on its proprietary Humabody VH platform—a patent-protected transgenic mouse (Crescendo Mouse) system that generates fully human variable heavy (VH) antibody fragments approximately one-tenth the size of conventional antibodies. This miniaturization confers superior tissue penetration, supports multiple administration routes (intravenous, subcutaneous, topical, pulmonary, oral, and ocular), and enables assembly into multi-specific Multibody VH formats via flexible linkers. The proprietary clinical pipeline includes CB307, a trispecific T cell enhancer targeting CD137, PSMA, and human serum albumin, currently in Phase 1b trials for PSMA-positive metastatic castration-resistant prostate cancer; CB699, a mesothelin-binding CD40/CD137 dual-agonist unveiled at AACR 2024; CB213, a PD-1xLAG-3 bispecific developed with Cancer Research UK; and CB693, a second clinical candidate nominated in 2022. Outside oncology, ZL-1102 (formerly CB001), an IL-17A-targeting Humabody licensed to Zai Lab, has progressed into a global Phase 2 trial in psoriasis following clinical proof-of-concept—the first study to show penetration of a protein biologic through psoriatic skin.

The company operates a partnership-driven, asset-light business model and does not commercialize products directly. Revenue is generated through upfront payments, R&D funding, and potential milestone and royalty streams from licensing and co-development agreements with pharmaceutical partners. Major deals include the 2016 Takeda strategic collaboration (up to $790 million in potential value, covering immuno-oncology modulators, Humabody drug conjugates, and later CAR-T applications), the 2022 BioNTech global multi-target precision immunotherapy collaboration, the 2018 Zai Lab exclusive worldwide license for inflammatory indications, and a 2020 Orano Med collaboration exploring targeted alpha therapy. To date, Crescendo has raised approximately £4.5M in seed funding (2009), £19.5M across Series A closes (2013–2014), $70M in Series B (2018, Andera Partners-led), and $32M in additional financing in July 2023 (with Kreos Capital as a new backer). The company is led by CEO Theodora Harold (appointed April 2019, previously CFO since 2016), with a specialized management team including CSO Philip Bland-Ward, CMO Dr. Kenji Hashimoto, CFO Dr. Michael Booth, and CBO Stewart Kay (ex-GSK). The organization employs 11–50 people, holds multiple granted US and European patents covering the Humabody VH platform, and continues to publish in leading journals (Clinical Cancer Research, British Journal of Cancer, Neoplasia) and present at AACR, ESMO, and PEGS.

Short descriptiontext

Crescendo Biologics is a Cambridge, UK-based clinical-stage immuno-oncology company developing T cell enhancing therapeutics using its proprietary Humabody VH antibody fragment platform, advancing proprietary candidates and licensing the technology to partners including Takeda, BioNTech, and Zai Lab.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
VH antibody platform, immuno-oncology therapeutics, T cell enhancement, antibody fragment therapeutics, transgenic mouse platform
Industry2 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Collaboration Agreements
TypeLicensing Royalties
Description

Crescendo generates revenue through strategic licensing and co-development agreements with pharmaceutical partners. The company enters global, multi-target collaborations where partners select targets and fund development, with potential milestone payments and royalties on commercialized products. Notable agreements include Takeda collaboration (up to $790m potential value), BioNTech global collaboration, and Zai Lab exclusive worldwide license.

crescendobiologics.com
2Equity Financing
TypeSubscription Recurring
Description

Company raises capital through equity funding rounds from institutional investors. Historical funding includes seed funding, Series A (£17.5M in 2013), Series B ($70M in 2018), and recent $32M financing (2023). Proceeds used to advance proprietary pipeline and clinical development.

pulse2.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Humabody VH Platform
Description

Proprietary platform technology for generating heavy-chain only antibody molecules (Humabodies) for therapeutic applications.

crescendobiologics.com
+1 more record
Core offering1 text field

Crescendo Biologics is a clinical-stage biopharmaceutical company developing T cell enhancing therapeutics for immuno-oncology based on its proprietary Humabody VH platform — a transgenic mouse platform generating fully human VH (variable heavy) antibody fragments roughly one-tenth the size of conventional antibodies. The company monetizes this technology through a pipeline of proprietary candidates (CB307, CB699, CB213, CB693) and through global multi-target licensing and co-development collaborations with major pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Clinical proof-of-concept declared for ZL-1102 (Humabody CB001) in Phase 1b trial in psoriasis patients - first study to demonstrate penetration of a protein biologic through psoriatic skin
+2 more records
Product overview1 text field

Crescendo Biologics is a clinical-stage immuno-oncology company developing novel T cell enhancing therapeutics based on its proprietary Humabody® VH platform. The platform generates fully human VH antibody fragments that are approximately one-tenth the size of conventional antibodies, enabling superior tissue penetration and multiple administration routes. The core products include CB307 (trispecific Humabody® targeting CD137/PSMA/HSA for PSMA+ tumors), CB699 (CD40/CD137 dual-agonist for MSLN+ tumors), CB213 (PD-1xLAG-3 bispecific), ZL-1102 (IL-17A targeting Humabody® for psoriasis, licensed to Zai Lab), and CB693 (second clinical candidate). The Humabody® platform underpins both proprietary pipeline development and strategic collaborations with BioNTech, Takeda, and Zai Lab. Multibody® VH format enables multi-specific therapeutic constructs with novel mechanisms of action.

Product and service5 records
1CB307
CategoryClinical-stage immuno-oncology therapeutic
Description

A trispecific Humabody® T cell enhancer co-targeting CD137, PSMA and human serum albumin, currently in Phase 1b clinical trials for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

2CB693
CategoryClinical-stage immuno-oncology therapeutic
Description

Second proprietary clinical candidate from Crescendo's immuno-oncology Humabody VH development portfolio, nominated for clinical development in July 2022.

3CB213
CategoryImmuno-oncology therapeutic (partner-developed)
Description

A PD-1xLAG-3 multi-specific Humabody that co-targets PD-1 and LAG-3 on T cells to promote anti-tumour activity, being clinically developed in partnership with Cancer Research UK.

4Humabody® VH Platform
CategoryProprietary antibody discovery platform
Description

Proprietary transgenic mouse platform generating fully human heavy-chain only VH antibody fragments (~1/10th the size of conventional antibodies) that underpin Crescendo's therapeutic pipeline and form the basis of its licensing deals with pharmaceutical partners.

5Multibody® VH
CategoryProprietary multi-specific antibody format
Description

Multi-specific, multi-functional therapeutic format assembled by linking multiple Humabody VH domains with flexible linkers, enabling novel mechanisms of action not achievable with standard monoclonal antibodies.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-10
Description

Global collaboration signed January 2022 to discover, develop and commercialise multi-specific precision immunotherapies. The multi-target collaboration leverages Crescendo's proprietary Humabody VH discovery platform with BioNTech's multimodal immunotherapy expertise. Targets selected by BioNTech with initial discovery collaboration term of three years.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-05
Description

Clinical Development Partnership signed May 2020 to develop CB213, a novel bispecific Humabody therapeutic. Cancer Research UK's Centre for Drug Development supporting clinical development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-03-06
Description

Pre-clinical collaboration signed March 2020 to explore Targeted Alpha Therapy. Crescendo's Humabody VH technology combined with Orano Med's lead-212 (212Pb) alpha isotope for precise cancer cell targeting while limiting impact on healthy cells.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-05-30
Description

Exclusive worldwide license agreement signed May 2018 for innovative protein therapeutics for inflammatory indications. ZL-1102 (formerly CB001) is a topically-delivered Humabody therapeutic for psoriasis. Clinical proof-of-concept declared after Phase 1b trial - first study to show penetration of a protein biologic through psoriatic skin.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-10-10
Description

Global strategic multi-target collaboration and license agreement signed October 2016 for development and commercialisation of Humabody therapeutics for cancer treatment. Targets include immuno-oncology modulators and Humabody drug conjugates (HDCs). Expanded in 2019 to include Humabody VH domains for Takeda's CAR-T therapies. Deal worth up to $790 million.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Crescendo Biologics

Biopharmaceutical Therapeuticscrescendobiologics.com

Crescendo Biologics is a Cambridge, UK-based clinical-stage immuno-oncology company developing T cell enhancing therapeutics using its proprietary Humabody VH antibody fragment platform, advancing proprietary candidates and licensing the technology to partners including Takeda, BioNTech, and Zai Lab.

What Crescendo Biologics does

Crescendo Biologics is a privately held, clinical-stage immuno-oncology company headquartered at the Babraham Research Campus in Cambridge, UK. Founded in 2009, the company develops novel T cell enhancing therapeutics built on its proprietary Humabody VH platform—a patent-protected transgenic mouse (Crescendo Mouse) system that generates fully human variable heavy (VH) antibody fragments approximately one-tenth the size of conventional antibodies. This miniaturization confers superior tissue penetration, supports multiple administration routes (intravenous, subcutaneous, topical, pulmonary, oral, and ocular), and enables assembly into multi-specific Multibody VH formats via flexible linkers. The proprietary clinical pipeline includes CB307, a trispecific T cell enhancer targeting CD137, PSMA, and human serum albumin, currently in Phase 1b trials for PSMA-positive metastatic castration-resistant prostate cancer; CB699, a mesothelin-binding CD40/CD137 dual-agonist unveiled at AACR 2024; CB213, a PD-1xLAG-3 bispecific developed with Cancer Research UK; and CB693, a second clinical candidate nominated in 2022. Outside oncology, ZL-1102 (formerly CB001), an IL-17A-targeting Humabody licensed to Zai Lab, has progressed into a global Phase 2 trial in psoriasis following clinical proof-of-concept—the first study to show penetration of a protein biologic through psoriatic skin.

The company operates a partnership-driven, asset-light business model and does not commercialize products directly. Revenue is generated through upfront payments, R&D funding, and potential milestone and royalty streams from licensing and co-development agreements with pharmaceutical partners. Major deals include the 2016 Takeda strategic collaboration (up to $790 million in potential value, covering immuno-oncology modulators, Humabody drug conjugates, and later CAR-T applications), the 2022 BioNTech global multi-target precision immunotherapy collaboration, the 2018 Zai Lab exclusive worldwide license for inflammatory indications, and a 2020 Orano Med collaboration exploring targeted alpha therapy. To date, Crescendo has raised approximately £4.5M in seed funding (2009), £19.5M across Series A closes (2013–2014), $70M in Series B (2018, Andera Partners-led), and $32M in additional financing in July 2023 (with Kreos Capital as a new backer). The company is led by CEO Theodora Harold (appointed April 2019, previously CFO since 2016), with a specialized management team including CSO Philip Bland-Ward, CMO Dr. Kenji Hashimoto, CFO Dr. Michael Booth, and CBO Stewart Kay (ex-GSK). The organization employs 11–50 people, holds multiple granted US and European patents covering the Humabody VH platform, and continues to publish in leading journals (Clinical Cancer Research, British Journal of Cancer, Neoplasia) and present at AACR, ESMO, and PEGS.

Crescendo Biologics firmographics

Firmographics
Name
Crescendo Biologics
Legal name
Crescendo Biologics Limited
Website
https://crescendobiologics.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Crescendo Biologics is a Cambridge, UK-based clinical-stage immuno-oncology company developing T cell enhancing therapeutics using its proprietary Humabody VH antibody fragment platform, advancing proprietary candidates and licensing the technology to partners including Takeda, BioNTech, and Zai Lab.
Ownership category
akta.pro rank

Crescendo Biologics industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • VH antibody platform
  • Immuno-oncology therapeutics
  • T cell enhancement
  • Antibody fragment therapeutics
  • Transgenic mouse platform

Where Crescendo Biologics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Crescendo Biologics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Collaboration Agreements: Crescendo generates revenue through strategic licensing and co-development agreements with pharmaceutical partners. The company enters global, multi-target collaborations where partners select targets and fund development, with potential milestone payments and royalties on commercialized products. Notable agreements include Takeda collaboration (up to $790m potential value), BioNTech global collaboration, and Zai Lab exclusive worldwide license.
  2. Equity Financing: Company raises capital through equity funding rounds from institutional investors. Historical funding includes seed funding, Series A (£17.5M in 2013), Series B ($70M in 2018), and recent $32M financing (2023). Proceeds used to advance proprietary pipeline and clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Crescendo Biologics product offering

Product offering

Core offering

Crescendo Biologics is a clinical-stage biopharmaceutical company developing T cell enhancing therapeutics for immuno-oncology based on its proprietary Humabody VH platform — a transgenic mouse platform generating fully human VH (variable heavy) antibody fragments roughly one-tenth the size of conventional antibodies. The company monetizes this technology through a pipeline of proprietary candidates (CB307, CB699, CB213, CB693) and through global multi-target licensing and co-development collaborations with major pharmaceutical partners.

Product overview

Crescendo Biologics is a clinical-stage immuno-oncology company developing novel T cell enhancing therapeutics based on its proprietary Humabody® VH platform. The platform generates fully human VH antibody fragments that are approximately one-tenth the size of conventional antibodies, enabling superior tissue penetration and multiple administration routes. The core products include CB307 (trispecific Humabody® targeting CD137/PSMA/HSA for PSMA+ tumors), CB699 (CD40/CD137 dual-agonist for MSLN+ tumors), CB213 (PD-1xLAG-3 bispecific), ZL-1102 (IL-17A targeting Humabody® for psoriasis, licensed to Zai Lab), and CB693 (second clinical candidate). The Humabody® platform underpins both proprietary pipeline development and strategic collaborations with BioNTech, Takeda, and Zai Lab. Multibody® VH format enables multi-specific therapeutic constructs with novel mechanisms of action.

Differentiator

Problem solved

Functional benefit

Brands

  • Humabody VH Platform: Proprietary platform technology for generating heavy-chain only antibody molecules (Humabodies) for therapeutic applications.
  • Multibody VH

Products and services

  • CB307 A trispecific Humabody® T cell enhancer co-targeting CD137, PSMA and human serum albumin, currently in Phase 1b clinical trials for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
  • CB693 Second proprietary clinical candidate from Crescendo's immuno-oncology Humabody VH development portfolio, nominated for clinical development in July 2022.
  • CB213 A PD-1xLAG-3 multi-specific Humabody that co-targets PD-1 and LAG-3 on T cells to promote anti-tumour activity, being clinically developed in partnership with Cancer Research UK.
  • Humabody® VH Platform Proprietary transgenic mouse platform generating fully human heavy-chain only VH antibody fragments (~1/10th the size of conventional antibodies) that underpin Crescendo's therapeutic pipeline and form the basis of its licensing deals with pharmaceutical partners.
  • Multibody® VH Multi-specific, multi-functional therapeutic format assembled by linking multiple Humabody VH domains with flexible linkers, enabling novel mechanisms of action not achievable with standard monoclonal antibodies.

Quantifiable outcome

  • Clinical proof-of-concept declared for ZL-1102 (Humabody CB001) in Phase 1b trial in psoriasis patients - first study to demonstrate penetration of a protein biologic through psoriatic skin
  • +2 more outcomes

Companies that use Crescendo Biologics

Customer profile

Segments2 records

Ideal customer profiles1 record

Crescendo Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Crescendo Biologics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • BioNTechcoreStrategic or Co-development Partner · 10 January 2022Global collaboration signed January 2022 to discover, develop and commercialise multi-specific precision immunotherapies. The multi-target collaboration leverages Crescendo's proprietary Humabody VH discovery platform with BioNTech's multimodal immunotherapy expertise. Targets selected by BioNTech with initial discovery collaboration term of three years.
  • Cancer Research UKminorStrategic or Co-development Partner · 5 May 2020Clinical Development Partnership signed May 2020 to develop CB213, a novel bispecific Humabody therapeutic. Cancer Research UK's Centre for Drug Development supporting clinical development.
  • Orano MedminorStrategic or Co-development Partner · 6 March 2020Pre-clinical collaboration signed March 2020 to explore Targeted Alpha Therapy. Crescendo's Humabody VH technology combined with Orano Med's lead-212 (212Pb) alpha isotope for precise cancer cell targeting while limiting impact on healthy cells.
  • Zai LabcoreOEM/ Whitelabel/ Licensing Partner · 30 May 2018Exclusive worldwide license agreement signed May 2018 for innovative protein therapeutics for inflammatory indications. ZL-1102 (formerly CB001) is a topically-delivered Humabody therapeutic for psoriasis. Clinical proof-of-concept declared after Phase 1b trial - first study to show penetration of a protein biologic through psoriatic skin.
  • Takeda Pharmaceutical Company LtdcoreStrategic or Co-development Partner · 10 October 2016Global strategic multi-target collaboration and license agreement signed October 2016 for development and commercialisation of Humabody therapeutics for cancer treatment. Targets include immuno-oncology modulators and Humabody drug conjugates (HDCs). Expanded in 2019 to include Humabody VH domains for Takeda's CAR-T therapies. Deal worth up to $790 million.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Crescendo Biologics competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Crescendo Biologics social profiles

Digital presence

Crescendo Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Crescendo Biologics leadership team

Management profile

Number of profiles

Profiles12 records

Crescendo Biologics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Crescendo Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crescendo Biologics

What does Crescendo Biologics do?

Crescendo Biologics is a clinical-stage biopharmaceutical company developing T cell enhancing therapeutics for immuno-oncology based on its proprietary Humabody VH platform — a transgenic mouse platform generating fully human VH (variable heavy) antibody fragments roughly one-tenth the size of conventional antibodies. The company monetizes this technology through a pipeline of proprietary candidates (CB307, CB699, CB213, CB693) and through global multi-target licensing and co-development collaborations with major pharmaceutical partners.

Is Crescendo Biologics a public or private company?

Crescendo Biologics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Crescendo Biologics founded?

Crescendo Biologics was founded in 2009. It employs 1 to 10 people.

Where is Crescendo Biologics based?

Crescendo Biologics is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Crescendo Biologics make money?

Two revenue lines are on record. Licensing and Collaboration Agreements are the primary driver. The others are equity Financing.

Does Crescendo Biologics have an API?

No public API is recorded for Crescendo Biologics.

What industry is Crescendo Biologics in?

Crescendo Biologics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireCrescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024Crescendo Biologics presented preclinical data on CB307 and CB699 at AACR 2024. CB307, a CD137 x PSMA bispecific, showed effective T and NK cell activation in prostate cancer models, supporting its Phase 1b trial. CB699, a mesothelin-directed dual agonist, also advanced toward clinical development.GlobeNewswireCrescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024Crescendo Biologics presented preclinical data on CB307 and CB699 at AACR 2024. CB307, a CD137 x PSMA bispecific, showed effective T and NK cell activation in prostate cancer models, supporting its Phase 1b trial. CB699, a mesothelin-directed dual agonist, demonstrated conditional CD40 and CD137 activation, supporting its progression to clinical development.GlobeNewswireCrescendo Biologics to present at the 2024 AACR Annual MeetingCrescendo Biologics will present two poster presentations at the 2024 AACR Annual Meeting in San Diego, covering its lead candidate CB307 and a mesothelin-binding dual-agonist. The posters are scheduled for Tuesday 9 April 2024, and details will be posted on the company's website.GlobeNewswireCrescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPCCrescendo Biologics announced that the first U.S. patients have been dosed in its Phase 1b trial of CB307, a bispecific antibody for PSMA+ metastatic castration-resistant prostate cancer. The trial, conducted at Fred Hutchinson Cancer Centre, includes monotherapy and combination with pembrolizumab cohorts. Recruitment continues at European sites.GlobeNewswireCrescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPCCrescendo Biologics announced that the first U.S. patients have been dosed in its Phase 1b trial of CB307 for PSMA+ metastatic castration-resistant prostate cancer. The trial, conducted at Fred Hutchinson Cancer Centre, includes monotherapy and combination with pembrolizumab cohorts. Recruitment continues at European sites.Pulse 2.0Crescendo Biologics: $32 Million Raised To Develop Targeted T Cell Enhancing TherapeuticsCrescendo Biologics has secured $32 million in additional financing to fund a new pembrolizumab combination expansion cohort for its lead drug candidate CB307. The funds, provided by existing shareholders and new investor Kreos Capital, will support the ongoing Phase 1b clinical trial for PSMA+ metastatic castration-resistant prostate cancer, with the new cohort expected to initiate in Q3 2023.Business Wire BlogCrescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumoursCrescendo Biologics secured $32M in financing to expand its CB307 Phase 1b trial in PSMA+ solid tumours, adding a pembrolizumab combination cohort. The new arm is expected to start in Q3 2023, following the monotherapy expansion already underway.GlobeNewswireBioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision ImmunotherapiesBioNTech and Crescendo Biologics announced a three-year collaboration to develop multi-specific immunotherapies using Crescendo's Humabody V H platform. Crescendo will receive $40 million upfront and is eligible for milestones up to $750 million plus royalties. BioNTech holds exclusive worldwide development and commercialization rights.PharmaTimesCrescendo Biologics expands Takeda collaborationCrescendo Biologics expanded its discovery and development collaboration with Takeda, following its sixth technical milestone. The expansion gives Takeda access to Crescendo's Humabody therapeutics for its two licensed oncology programmes. The companies aim to advance novel cancer therapies.The Pharma LetterBRIEF—Adaptate appoints chief business officerAdaptate Biotherapeutics appointed Stewart Kay as chief business officer, bringing experience from Crescendo Biologics, GlaxoSmithKline, and other firms. The company focuses on antibody-based therapeutics for gamma delta T cell modulation. CEO Natalie Mount said the appointment supports the next phase of development.